more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$126.78 USD

+0.61 (0.48%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $126.86 +0.08 (0.06%) 6:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

Top 25% (63 out of 251)

Industry: Medical - Instruments

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Hold on to Nevro (NVRO) Stock Now

by Zacks Equity Research Published on July 02,2019

Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, severe rivalry is a lingering woe.

medical

Here's Why You Should Invest in Integer Holdings (ITGR) Stock

by Zacks Equity Research Published on June 11,2019

Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.

medical

Why Is Integer (ITGR) Down 1.7% Since Last Earnings Report?

by Zacks Equity Research Published on June 01,2019

Integer (ITGR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ITGRPositive Net Change

Integer Holdings (ITGR) Q1 Earnings & Revenues Top Estimates

by Zacks Equity Research Published on May 06,2019

Top-line growth and better performance at Medical and Non-Medical segments benefit Integer Holdings' (ITGR) Q1 results. However, contraction in gross margin remains a dampener.

Integer (ITGR) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research Published on May 02,2019

Integer (ITGR) delivered earnings and revenue surprises of 25.00% and 3.48%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

ITGRPositive Net Change

Integer Holdings (ITGR) Q1 Earnings: What's in the Cards?

by Zacks Equity Research Published on April 29,2019

Better-than-expected performance at C&V and Cardiac & Neuromodulation product lines and higher revenues might aid Integer Holdings (ITGR) in Q1. But decline in non-medical sales might be a dampener.

Integer (ITGR) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research Published on April 25,2019

Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ITGRPositive Net Change

New Strong Buy Stocks for April 22nd

by Nitish Marwah Published on April 22,2019

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

New Strong Buy Stocks for April 16th

by Tirthankar Chakraborty Published on April 16,2019

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

Integer (ITGR) Gains But Lags Market: What You Should Know

by Zacks Equity Research Published on April 12,2019

Integer (ITGR) closed at $77.10 in the latest trading session, marking a +0.19% move from the prior day.

ITGRPositive Net Change

Integer Holdings Gets Positive Outlook & B+ Rating From S&P

by Zacks Equity Research Published on April 01,2019

Integer (ITGR) strengthens its balance sheet by reducing its leverage ratio from 5.6X at the end of 2017 to 3.5X at 2018 end.

medical

AngioDynamics' Latest FDA Approval to Boost Oncology Unit

by Zacks Equity Research Published on March 29,2019

AngioDynamics' (ANGO) OARtrac is the first of its kind radiation dose monitoring platform.

medical

New Strong Buy Stocks for March 27th

by Nitish Marwah Published on March 27,2019

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.

Zimmer Biomet's FDA 510(k) Nod Widens Robotic Offerings

by Zacks Equity Research Published on March 26,2019

With the FDA nod, Zimmer Biomet (ZBH) attains the status of being the first company to boast the 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform globally.

medical

Here's Why You Should Invest in Genomic Health (GHDX) Now

by Zacks Equity Research Published on March 25,2019

Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now making considerable expansion in the international arena.

medical

Abbott's New CE Mark to Boost Core Laboratory Diagnostics Arm

by Zacks Equity Research Published on March 25,2019

Abbott's (ABT) Alinity m diagnostics system and assays will provide increased flexibility and time efficiency while catering to the rising demand for infectious disease testing.